Clopidogrel
Product Images NDC 63629-4728

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 63629-4728). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image 1

Chemical structure of Clopidogrel sulfate showing its molecular arrangement with key functional groups including a thiophene ring, a methyl ester, and a chlorophenyl group.*

FDA Label Image

Image 10

A forest plot comparing Clopidogrel and Aspirin by qualifying conditions: Stroke, MI, PAD, and Overall. The plot displays hazard ratios with 95% confidence intervals, showing favorability between Clopidogrel and Aspirin for each condition and overall. Numerical data includes patient counts and percentages for each treatment group.*

FDA Label Image

Image 2

A horizontal error bar chart showing the effect of various coadministered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) of clopidogrel. The chart compares mean changes and 90% confidence intervals for Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg relative to clopidogrel administered alone.*

FDA Label Image

Image 3

A line graph comparing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up for patients on Clopidogrel (+ aspirin) versus placebo (+ aspirin). The graph shows lower event rates for Clopidogrel with statistical significance noted (P = 0.00009).*

FDA Label Image

Image 4

A forest plot chart depicting hazard ratios (with 95% confidence intervals) for the effect of Clopidogrel versus placebo across various patient subgroups based on age, gender, race, elevated cardiac enzymes, diabetes, previous myocardial infarction, and previous stroke. The chart includes sample sizes and event counts (n, %) for Clopidogrel and placebo groups, illustrating subgroup comparative risks and overall outcomes.*

FDA Label Image

Image 5

A forest plot displaying hazard ratios with 95% confidence intervals comparing Clopidogrel and placebo across various subgroups, including Heparin/LMWH, Aspirin dosage, GPIIb/IIIa antagonist use, Beta-blocker use, and ACE inhibitor use, as well as the overall population.*

FDA Label Image

Image 6

A Kaplan-Meier survival curve comparing the percentage of deaths before first discharge over 28 days post-randomization between Clopidogrel and placebo groups. The graph shows a lower death percentage for Clopidogrel with 1726 deaths (7.5%) versus 1845 deaths (8.1%) for placebo, indicating a 7% proportional risk reduction (p = 0.03).*

FDA Label Image

Image 7

A Kaplan-Meier curve showing the percentage of patients experiencing death, re-infarction, or stroke before first discharge over days since randomization (up to 28 days). It compares outcomes for patients treated with Clopidogrel versus placebo, illustrating a lower event rate for Clopidogrel with a reported 9% proportional risk reduction.*

FDA Label Image

Image 8

A data table presenting subgroup analyses comparing Clopidogrel and placebo across various demographics and clinical characteristics including gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The table includes sample sizes, event counts, percentages, and an odds ratio plot showing favorability toward Clopidogrel or placebo with confidence intervals.*

FDA Label Image

Image 9

A line graph comparing the cumulative event rate percentage of fatal or non-fatal vascular events over a 36-month follow-up period between aspirin and clopidogrel. The graph shows two distinct lines representing each drug, with event rates rising over time. A p-value of 0.045 is noted on the graph.*

FDA Label Image

Lbl636294728

Clopidogrel 75mg Tablet label packaged by Bryant Ranch Prepack, Burbank, CA. The label compares this product to Plavix 75mg Tablet by Teva Pharmaceutical Industries. It indicates a quantity of 90 tablets and has storage instructions to keep tightly closed and store at room temperature 20°-25°C (68°-77°F). The label includes the product NDC 63629-47281 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.